Home

Wendy S. Johnson

CIK 1652822 · Chief Development Officer · last filed 2023-06-13

Wendy S. Johnson is a Chief Development Officer who has filed 11 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for XGN, was dated Jun 13, 2023. Across all open-market trades the lifetime net is −$931.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.6K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$7.6K

Companies

3

Total Filings

11

Lifetime Open-Market Net

-$931.3K

Filer Profile

Reported Address
800 E. LEIGH STREET
SUITE 209
RICHMOND, VA 21219
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XGN Director 1,000 $7.58 $7.6K $14.0K 5 2023-06-13
OnKure Therapeutics, Inc. (RPHM) Delisted Chief Development Officer 0 $18.20 $0 -$949.8K 2 2021-07-15
Armata Pharmaceuticals, Inc. (APHB) Delisted Interim Chief Operating Office 71 — — $4.4K 4 2017-09-11

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-13 XGN Grant (A) — $0 EDGAR
2022-06-21 XGN Grant (A) — $0 EDGAR
2021-09-07 XGN Buy (P) +1,000 $14.0K EDGAR
2021-07-15 OnKure Therapeutics, Inc. (RPHM) Delisted Sell (S) −111,736 -$949.8K EDGAR
2021-07-09 OnKure Therapeutics, Inc. (RPHM) Delisted Exer (M) +111,736 $220.1K EDGAR
2021-06-21 XGN Grant (A) — $0 EDGAR
2020-10-01 XGN Grant (A) — $0 EDGAR
2017-09-11 Armata Pharmaceuticals, Inc. (APHB) Delisted Grant (A) — $0 EDGAR
2015-10-07 Armata Pharmaceuticals, Inc. (APHB) Delisted Buy (P) +1,000 $4.4K EDGAR
2015-09-23 Armata Pharmaceuticals, Inc. (APHB) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.